Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Abbott Laboratories : Abbott Announces Effectiveness of AbbVie Form 10 Registration Statement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2012 | 11:50pm CET

ABBOTT PARK, Ill., Dec. 7, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the Securities and Exchange Commission (SEC) has declared effective the Form 10 Registration Statement filed by AbbVie Inc., its research-based pharmaceuticals business. Abbott expects to complete the separation of AbbVie on Jan. 1, 2013.

On Nov. 28, 2012, Abbott's board of directors approved the separation of AbbVie, and declared a special dividend distribution of one share of AbbVie common stock for each Abbott common share outstanding as of the close of business on Dec. 12, 2012, the record date for the distribution. Abbott expects the special dividend of AbbVie stock will be distributed on Jan. 1, 2013.

There is no current market for AbbVie common stock. The New York Stock Exchange (NYSE) has authorized the listing of AbbVie common stock under the symbol "ABBV" following the distribution. AbbVie has been advised that trading in its common stock is expected to begin on a "when issued" basis on Dec. 10, 2012, under the symbol "ABBV.WI." "When issued" trading of AbbVie common stock will continue until Abbott pays the special dividend distribution of AbbVie common stock on Jan. 1, 2013. AbbVie "when issued" trades will settle after Jan. 1, 2013, with shares of AbbVie as a standalone company.

Beginning on Dec. 10, 2012, and continuing through Dec. 31, 2012, Abbott expects that common shares of Abbott will trade in two markets on the NYSE: "regular-way" under the symbol "ABT" and in the "ex-distribution" market under the symbol "ABT.WI." Abbott shares trading under "ABT" will carry the right to receive shares of AbbVie through the special dividend distribution. Abbott shares trading under "ABT.WI" will not carry the right to receive shares of AbbVie through the special dividend distribution.

Abbott shareholders who sell their shares in the "regular-way" market before Jan. 1, 2013, will also be selling their entitlement to receive the AbbVie special dividend distribution of AbbVie common stock. Abbott shareholders are encouraged to consult with their financial advisors regarding the specific consequences of selling Abbott common shares on or before Dec. 31, 2012.

On Jan. 2, 2013, regular-way trading will commence on the NYSE for AbbVie under the symbol "ABBV" and will continue for Abbott under the symbol "ABT."

AbbVie will be a research-based specialty biopharmaceuticals company with a broad portfolio of medicines, including leadership in immunology and virology, and a pipeline of breakthrough therapies. Abbott will be one of the largest science-based healthcare companies with diversified market-leading offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals - all aligned with favorable healthcare trends.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 91,000 people and markets its products in more than 130 countries.

- Private Securities Litigation Reform Act of 1995 -
A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995, including the planned separation of the research-based pharmaceutical company from the diversified medical products company and the expected financial results of the two companies after the separation. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2011 and in Item 1A, "Risk Factors," to our quarterly report on Securities and Exchange Commission Form 10-Q for the quarter ended Sept. 30, 2012 and June 30, 2012, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

SOURCE Abbott

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
09:59p ABBOTT LABORATORIES : Trademark Application for "IMFED" Filed by Abbott Laborato..
09:53p ABBOTT LABORATORIES : An Application for the Trademark "TENDRIL MRI" Has Been Fi..
07:21p ABBOTT LABORATORIES : Trademark Application for "DECISIONTX" Filed by Abbott Lab..
07:11p ABBOTT LABORATORIES : An Application for the Trademark "IMFED FOR CHILDREN" Has ..
03/22 ABBOTT LABORATORIES (NYSE : ABT) Files An 8-K Creation of a Direct Financial Obl..
03/22 ABBOTT LABORATORIES : Creation of a Direct Financial Obligation or an Obligation..
03/22 ABBOTT LABORATORIES : Recent Developments in the Electrophysiology Markets
03/22 ABBOTT : Hosts Conference Call for First-Quarter Earnings
03/21 ABBOTT LABORATORIES PAKISTAN : Annual general meeting of Abbott Laboratories Pak..
03/21 ABBOTT LABORATORIES : Higher risk seen with Abbott dissolving stent
More news
Sector news : Pharmaceuticals - NEC
10:46pDJPRESS RELEASE : FDA Grants Approval for -3-
10:46pDJPRESS RELEASE : FDA Grants Approval for -2-
10:46pDJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
09:32p SEC charges two Israeli residents with Mobileye insider trading
11:53a TEVA PHARMACEUTICAL INDUSTRIES : Pharm says media reports of up to 6,000 layoffs..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02:23p Pharma Development Budgets Grow As Roche Remains A Believer
03/21 Biotechs under pressure after Trump (again) decries high drug prices
03/19 5 Dividend Investing Success Stories And 5 New Ideas Based On These Findings
03/19 Low Volatility And High Beta Stocks Prior To Last Downturn
03/16 Abbott Laboratories' (ABT) Management Presents at Barclays Capital 2017 Globa..